What is Bryn Pharma?
Bryn Pharma operates at the intersection of biotechnology and patient-centric healthcare, specifically targeting the critical need for accessible anaphylaxis management. The company is currently developing NDS1C, a needle-free epinephrine nasal spray designed to eliminate the physical and psychological barriers associated with traditional auto-injectors. By prioritizing ease of use and portability, Bryn Pharma addresses a significant gap in the emergency medical market, where rapid intervention is essential. Their business model is built upon the premise that medical innovation should be driven by the lived experiences of patients, ensuring that their therapeutic solutions are both intuitive and highly effective for non-medical personnel in high-stress environments.
How much funding has Bryn Pharma raised?
Bryn Pharma has raised a total of $26M across 1 funding round:
Private Equity
$26M
Private Equity (2020): $26M with participation from Undisclosed
Key Investors in Bryn Pharma
Undisclosed Investors
What's next for Bryn Pharma?
With the recent infusion of capital, Bryn Pharma is poised to scale its operational infrastructure and navigate the final stages of regulatory approval for its flagship product. The company's strategic roadmap focuses on optimizing manufacturing processes and expanding its distribution network to ensure that NDS1C reaches the patient populations that need it most. As the firm moves into this growth phase, the focus will likely shift toward establishing key partnerships with healthcare providers and insurance entities to facilitate widespread adoption. By maintaining its commitment to affordability and accessibility, Bryn Pharma is set to disrupt the standard of care for anaphylaxis, potentially setting a new benchmark for emergency drug delivery systems in the global pharmaceutical landscape.
See full Bryn Pharma company page
